drugset / Trial / NCT00118365

Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps

NCT00118365

Phase 3 Completed 375 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupDouble-blindPrevention

Summary

This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer

Timeline

Start
1998-07
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Eflornithine Small molecule Oral
Subject Sulindac Small molecule Oral